EGFR and cancer: For example, embolism (n=21, ROR=4.93), venous thrombosis (n=16, ROR=8.16), infarction (n=8, ROR=2.47), deep vein thrombosis (n=71, ROR=2.11), etc. A meta-analysis showed that cancer patients on anti-EGFR monoclonal antibody-containing therapies are roughly 1.5 times more likely to experience venous or pulmonary embolism compared to those receiving the same therapies without anti-EGFR mAbs20.